Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLS NASDAQ:ERAS NASDAQ:ESPR NASDAQ:SAVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$7.58-0.9%$8.54$5.71▼$17.82$490.27M1.121.11 million shs677,311 shsERASErasca$1.58-1.3%$1.49$1.01▼$3.31$448.20M1.071.36 million shs396,165 shsESPREsperion Therapeutics$2.18-0.5%$1.46$0.69▼$3.94$439.53M0.824.80 million shs4.34 million shsSAVACassava Sciences$2.31+2.7%$2.16$1.15▼$33.98$111.60M-2.051.40 million shs633,964 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus+2.96%+7.29%-19.73%-17.74%-51.61%ERASErasca+0.63%+5.26%-8.05%+45.45%-44.83%ESPREsperion Therapeutics+1.86%+7.35%+45.03%+162.37%+24.43%SAVACassava Sciences+4.17%+2.74%-4.26%+7.14%-92.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEOLSEvolus4.1291 of 5 stars3.41.00.03.53.33.30.6ERASErasca2.1333 of 5 stars3.41.00.00.01.92.50.6ESPREsperion Therapeutics3.7528 of 5 stars3.41.00.03.92.41.70.6SAVACassava Sciences1.9553 of 5 stars1.01.00.04.72.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 2.80Moderate Buy$21.25180.34% UpsideERASErasca 2.86Moderate Buy$4.29171.25% UpsideESPREsperion Therapeutics 2.80Moderate Buy$7.00221.10% UpsideSAVACassava Sciences 2.00Hold$2.00-13.42% DownsideCurrent Analyst Ratings BreakdownLatest SAVA, ERAS, EOLS, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025ERASErascaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.00 ➝ $2.008/6/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $18.008/6/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$27.00 ➝ $20.008/6/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$22.006/17/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$266.27M1.84N/AN/A($0.29) per share-26.14ERASErascaN/AN/AN/AN/A$1.31 per shareN/AESPREsperion Therapeutics$332.31M1.32$0.02 per share89.49($2.15) per share-1.01SAVACassava SciencesN/AN/AN/AN/A$1.82 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)ERASErasca-$161.65M-$0.45N/AN/AN/AN/A-31.19%-26.34%11/11/2025 (Estimated)ESPREsperion Therapeutics-$51.74M-$0.49N/AN/AN/A-35.84%-0.91%-28.41%11/6/2025 (Estimated)SAVACassava Sciences-$24.34M-$2.55N/AN/AN/AN/A-66.16%-53.11%11/13/2025 (Estimated)Latest SAVA, ERAS, EOLS, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SAVACassava SciencesN/A-$0.18N/A-$0.92N/AN/A8/12/2025Q2 2025ERASErasca-$0.12-$0.12N/A-$0.12N/AN/A8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolus22.002.271.86ERASErascaN/A11.0311.04ESPREsperion TherapeuticsN/A1.150.76SAVACassava SciencesN/A2.432.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%ERASErasca67.78%ESPREsperion Therapeutics47.39%SAVACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipEOLSEvolus6.10%ERASErasca14.40%ESPREsperion Therapeutics1.70%SAVACassava Sciences12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17064.68 million60.74 millionOptionableERASErasca120283.67 million242.82 millionOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableSAVACassava Sciences3048.31 million42.41 millionOptionableSAVA, ERAS, EOLS, and ESPR HeadlinesRecent News About These CompaniesCassava Technologies Unveils AI Factory for Africa, Powered by NVIDIA SupercomputersAugust 25 at 11:11 AM | thezimbabwemail.comTCassava Sciences (NASDAQ:SAVA) Announces Quarterly Earnings ResultsAugust 18, 2025 | marketbeat.comCassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | finanznachrichten.deCassava Sciences reports Q2 EPS (92c) vs 13c last yearAugust 14, 2025 | msn.comCassava Reports Q2 2025 Financials Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical OfficerAugust 7, 2025 | globenewswire.comGinkgo Bioworks Holdings Q2 Earnings PreviewAugust 6, 2025 | msn.comCassava Sciences Announces Positive Preclinical ResultsAugust 6, 2025 | theglobeandmail.comCassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related EpilepsyAugust 4, 2025 | globenewswire.comSAVA - Cassava Sciences Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMCassava Sciences presents poster at TSC 2025 on SimufilamJune 30, 2025 | msn.comCassava Presents Promising Preclinical Simufilam Data at TSC Alliance MeetingJune 30, 2025 | globenewswire.comSAVA Stock Price for Cassava Sciences Inc - MorningstarJune 28, 2025 | morningstar.comMWhy cassava could be a great addition to a balanced dietJune 26, 2025 | msn.comCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava gives AI firm access to its collection of GPUsMay 19, 2025 | htxt.co.zaHCassava partners with Zindi to give African AI developers better toolsMay 15, 2025 | techzim.co.zwTCassava Sciences Inc.May 15, 2025 | barrons.com5 ON YOUR SIDE: Lead levels in cassava flourMay 15, 2025 | kstp.comKCassava Technologies, Zindi collaborate on AI servicesMay 12, 2025 | msn.comCassava Technologies and Zindi collaborate to showcase African A.I. innovationMay 12, 2025 | thezimbabwemail.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAVA, ERAS, EOLS, and ESPR Company DescriptionsEvolus NASDAQ:EOLS$7.58 -0.07 (-0.92%) Closing price 04:00 PM EasternExtended Trading$7.58 0.00 (-0.07%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Erasca NASDAQ:ERAS$1.58 -0.02 (-1.25%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Esperion Therapeutics NASDAQ:ESPR$2.18 -0.01 (-0.46%) Closing price 04:00 PM EasternExtended Trading$2.18 0.00 (0.00%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Cassava Sciences NASDAQ:SAVA$2.31 +0.06 (+2.67%) Closing price 04:00 PM EasternExtended Trading$2.31 0.00 (-0.22%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Vertical Aerospace: An Analyst's Roadmap to a Potential Re-Rating AEHR Spikes 36% on Hyperscaler Order—Investors Should Take Notice From Debt to Liftoff: EchoStar's $23 Billion Catalyst Buffett’s Wisdom Could Spell Trouble for Palantir Shorts Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access